Genetic therapies represent a remarkable avenue for potentially slowing and preventing neurodegenerative diseases. This includes a first-in-human, gene-silencing treatment for Alzheimer’s disease. Find out more on this from Catherine Mummery.
In this video, we spoke with Henrik Zetterberg to find out how challenges with replication, reproducibility and specificity could be addressed in the field.
A blood test to diagnose individuals at risk of developing Alzheimer’s disease before symptoms arise may be closer to reality, as researchers report a 94% accuracy in recent findings.
In this interview, Jeffrey Cummings speaks to us about the current landscape around antibody therapeutics for Alzheimer’s disease.
This week in industry we’re taking a look at the discontinuation of umibecestat and Acthar® Gel for Alzheimer’s and ALS, respectively, as well as the drug discovery shift from the amyloid approach in the Alzheimer’s field.
New studies presented at AAIC 2019 reveal that sex-specific differences could play a role in the risk, progression and resilience of Alzheimer’s disease.
Studies presented at AAIC 2019 have revealed the significant advances being made in the global search for blood-based biomarkers for dementia.
Observational studies reveal that use of sleep medications can increase an individual’s chances of developing dementia in sex-specific and race-specific ways.
Studies presented at AAIC 2019 provide potential treatment methods for the improvement of sleep quality in individuals with dementia.
New studies reported at AAIC 2019 are addressing the evolving and expanding role of technology in dementia care, prevention and alleviating burden.
